3 New Strong Buy Ratings from Top-Rated Analysts: 08/07/2025

Looking for some stock ideas? Here’s what’s hot, according to our most popular screener:

• Demand isn’t dwindling for Cardinal Health’s (CAH) vital services 
• Analysts are bullish on Niagen Bioscience (NAGE) — here’s why 
• Why Myr Group (MYRG) is the top-rated stock in its industry

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...
Apple's Starlink Update Sparks Huge Earning Opportunity  

Apple just secretly added Starlink satellite support to iPhones through iOS 18.3.  
One of the biggest potential winners? Mode Mobile.  
Mode's EarnPhone already reaches 50M+ users that have earned over $325M, and that's before global satellite coverage. With SpaceX eliminating "dead zones" worldwide, Mode's earning technology can now reach billions more in unbanked and rural populations worldwide.  
Their global expansion is perfectly timed, and you still have a chance to invest in their pre-IPO offering at just $0.30/share. Final allocations are disappearing quickly.  
Mode's recent 32,481% revenue growth and their newly reserved Nasdaq ticker $MODE puts them one step closer to a potential IPO.  

 ⏰ Almost sold out - invest now at $0.30/share now  
Disclosure: Mode Mobile recently received their ticker reservation with Nasdaq ($MODE), indicating an intent to IPO in the next 24 months. An intent to IPO is no guarantee that an actual IPO will occur. Please read the offering circular and related risks at invest.modemobile.com.  

1. Niagen Bioscience (NASDAQ: NAGE) 

Niagen Bioscience has patented a form of nicotinamide riboside (NR), which has recently demonstrated promising results in the treatment of Werner syndrome in a phase 1 trial. NAGE has already rallied by 64.96% on a year-to-date (YTD) basis, and both Wall Street researchers and our system have it pegged as a likely performer going forward.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $9.16 — get current quote > 

Max 1-year forecast: $23.00 

Why we’re watching:

• Niagen Bioscience shares currently have 3 Strong Buy ratings and 1 Buy rating — there are currently no Hold, Sell, or Strong Sell ratings for the stock. See the ratings
• In addition, the average price target for NAGE, currently pegged at $14.53, implies a hefty 60.67% upside.  
• Canaccord Genuity’s Susan Anderson (a top 9% rated analyst) recently maintained a Strong Buy rating on Niagen Bioscience, and increased her price target from $13 to $16.
• Anderson said they hiked their price target on the heels of the 2025/06/09 announcement of positive results of the first clinical study demonstrating the safety and efficacy of Niagen Bioscience’s patented nicotinamide riboside (NR) ingredient, Niagen®, in individuals with Werner syndrome (WS), a rare genetic disorder giving rise to rapid aging and premature mortality.
• The analyst called a "positive first step" that the published double-blind and placebo-controlled study highlighted the safety of NAD+ supplementation on patients with WS and also helped significantly increase NAD+ levels in blood by ~140%, along with improving various clinical markers for those with WS.
• NAGE ranks in the 93rd percentile of the stocks that our system tracks, giving it a Zen Rating of B
• Sentiment is one area where NAGE shines — 70.37% of the insider transactions tied to the stock in the past 12 months have been buys. Couple that with positive analyst coverage and recent increases in price targets, and it’s no wonder that the stock ranks in the top 21% in this area.
• In terms of their Growth Component Grade rating, Niagen Biosciences shares rank in the top 13%.
• However, the company’s balance sheet is the star of the show — Niagen Bioscience ranks in the top 3% of equities when it comes to Financials. (See all 7 Zen Component Grades here >)

2. Myr Group (NASDAQ: MYRG)

Myr Group is a specialty contractor that builds and maintains electrical infrastructure across the U.S. and Canada. Its main focuses are high-voltage power lines, substations, and electrical work for large-scale industrial projects. With electrification showing no signs of stopping — coupled with constant calls for grid modernization, MYRG is set to benefit from steady demand.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $187.46 — get current quote > 

Max 1-year forecast: $211.00 

Why we’re watching:

• Myr Group stock currently has 3 Strong Buy ratings, 1 Buy rating, and 2 Hold ratings. Notably, there are no Sell or Strong Sell ratings. See the ratings
• KeyBanc’s Sangita Jain (a top 9% rated analyst) doubled down on a Strong Buy rating on the stock following the company’s Q2 2025 earnings, and increased her price target from $205 to $211.
• Jain said the "strong" results were highlighted by consensus-beating EPS.
• The quarter generated previously indicated mid-to-high-single-digit core revenue growth in both segments in 2H 2025, the analyst continued, with decent project bookings momentum in both segments.
• The stock price has responded favorably to improved execution and a lower-risk MSA-driven project profile, Jain said, looking ahead.
• MYRG is the top-rated stock in the Engineering & Construction industry, which has an Industry Rating of A.
• MYRG shares rank in the top 2% of the equities that we track, giving them a Zen Rating of A.
• Roughly 29% of the insider transactions tied to MYRG in the past 12 months have been buys — once we factor in positive analyst coverage, it comes as little surprise that the stock ranks in the top 14% of equities in terms of Sentiment.
• Myr Group shares have rallied by 27.42% in the past three months — and rank in the 89th percentile when it comes to Momentum.
• However, the stock’s Growth Component Grade rating is the star of the show — in this regard, MYRG ranks in the top 1% of equities. (See all 7 Zen Component Grades here >)

3. Cardinal Health (NYSE: CAH) 

Cardinal Health has become a $35 billion medical distribution powerhouse in the more than half a century that it has been operating. The company currently provides supplies such as gloves, surgical apparel, and fluid management products to three-quarters of the hospitals in the United States.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $158.24 — get current quote > 

Max 1-year forecast: $190.00 

Why we’re watching:

• Analyst coverage of Cardinal Health tends toward the bullish side — the stock currently has 4 Strong Buy ratings, 3 Buy ratings, and 1 Hold rating. See the ratings
• Morgan Stanley equity researcher Erin Wright (a top 6% rated analyst) recently doubled down on a Strong Buy rating on CAH, and upped her price target from $181 to a Street-high $190.
• Cardinal Health is currently the top-rated stock in the Medical Distribution industry, which has an Industry Rating of A.
• CAH shares rank in the top 5% of the equities that our system tracks, giving them a Zen Rating of A, equivalent to a Strong Buy rating.
• Growth is one of Cardinal Health’s strong suits — in this regard, the stock ranks in the top 18%.
• Our Sentiment Component Grade rating takes into account analyst ratings, insider selling/buying, and short interest — and in this category, CAH shares rank in the 92 nd percentile of equities.
• However, Safety is the biggest advantage that CAH has — on account of stable stock price and predictable earnings, Cardinal Health ranks in the top 1% in terms of this Component Grade rating. (See all 7 Zen Component Grades here >)

What to Do Next?

• 9 Special Stock Lists You Need Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.